Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yeo Jin Choi, Dae Jung Kim & Sooyoung Shin. (2019) Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus. Cancer Management and Research 11, pages 7427-7438.
Read now
Read now
Yoojin Noh, Sukhyang Lee & Sooyoung Shin. (2018) Durability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patients. Therapeutics and Clinical Risk Management 14, pages 1563-1571.
Read now
Read now
Valentina Lorenzoni, Fabio Baccetti, Stefano Genovese, Enrico Torre & Giuseppe Turchetti. (2017) Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. ClinicoEconomics and Outcomes Research 9, pages 699-710.
Read now
Read now
Articles from other publishers (3)
Maria Greabu, Silviu Constantin Badoiu, Iulia-Ioana Stanescu-Spinu, Daniela Miricescu, Alexandra Ripszky Totan, Silvia Elena Badoiu, Michel Costagliola & Viorel Jinga. (2021) Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review. International Journal of Molecular Sciences 22:18, pages 9782.
Crossref
Crossref
Hyouk-Jun Chin, Jin Hyun Nam, Eui-Kyung Lee & Ju-Young Shin. (2017) Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes. Medicine 96:25, pages e7213.
Crossref
Crossref
Lesley J. Scott. (2017) Sitagliptin: A Review in Type 2 Diabetes. Drugs 77:2, pages 209-224.
Crossref
Crossref